Indirect assessment of dihydropyrimidine dehydrogenase activity in cats

Veterinary and Comparative Oncology

Volumn 11, Issue 4, 2013, Pages 265-271

  Saba, C F ^a   Schmiedt, C W ^a   Freeman, K G ^a   Edwards, G L ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Chemotherapy; Comparative oncology; Epidemiology; Oncology; Small animal

Indexed keywords

ANIMALIA;

ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; DRUG DERIVATIVE; FLUOROURACIL; URACIL;

AGING; ANIMAL; ARTICLE; BLOOD; CAT; CAT DISEASE; CHEMICALLY INDUCED DISORDER; CHEMOTHERAPY; COMPARATIVE ONCOLOGY; DRUG EFFECT; EPIDEMIOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; ONCOLOGY; SMALL ANIMAL;

CHEMOTHERAPY; COMPARATIVE ONCOLOGY; EPIDEMIOLOGY; ONCOLOGY; SMALL ANIMAL;

AGING; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CAT DISEASES; CATS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; URACIL;

EID: 84886639984     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12064     Document Type: Article

References (32)

1. Harvey HJ, MacEwen EG and Hayes AA. Neurotoxicosis associated with use of 5-fluorouracil in five dogs and one cat. Journal of the American Veterinary Medical Association 1977; 171: 277-278.
2. Henness AM, Theilen GH, Madewell BR and Crow SE. Neurotoxicosis associated with use of 5-florouracil. Journal of the American Veterinary Medical Association 1977; 171: 692.
3. Theilen G. Adverse effect from use of 5% fluorouracil. Journal of the American Veterinary Medical Association 1987; 191: 276.
4. Grem J. 5-Fluoropyrimidines. In: Cancer Chemotherapy s Biotherapy. 4th edn., B Chabner and D Longo Eds., Philadelphia, Lippincott Williams & Wilkins, 2006: 125-182.
5. Ben Fredj R, Gross E, Chouchen L, B'Chir F, Ben Ahmed S, Neubauer S, Kiechle M and Saguem S. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. Comptes Rendus Biologies 2007; 330: 764-769.
6. Diasio RB and Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clinical Cancer Research 1999; 5: 2672-2673.
7. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F and Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients. Journal of Clinical Oncology 1994; 12: 2248-2253.
8. Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, Francoual M, Renée N, Ferrero JM, Foa C, Namer M, Lacarelle B and Milano G. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clinical Cancer Research 2006; 12: 5496-5502.
9. Ogura K, Ohnuma T, Minamide Y, Mizuno A, Nishiyama T, Nagashima S, Kanamaru M, Hiratsuka A, Watabe T and Uematsu T. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clinical Cancer Research 2005; 11: 5104-5111.
10. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML and Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. New England Journal of Medicine 1985; 313: 245-249.
11. Diasio RB, Beavers TL and Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. Journal of Clinical Investigation 1988; 81: 47-51.
12. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR and Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clinical Cancer Research 2004; 10: 2652-2658.
13. Ezzeldin H, Johnson MR, Okamoto Y and Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clinical Cancer Research 2003; 9: 3021-3028.
14. Inada M, Hirao Y, Koga T, Itose M, Kunizaki J, Shimizu T and Sato H. Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and DPD-deficient dogs. Drug Metabolism and Disposition 2005; 33: 381-387.
15. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A and Gamelin E. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Letters 2007; 249: 271-282.
16. Lu Z, Zhang R and Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Research 1993; 53: 5433-5438.
17. Jiang H, Lu J and Ji J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. British Journal of Pharmacology 2004; 141: 616-623.
18. Ben Fredj R, Gross E, Ben Ahmed S, Hassine H and Saguem S. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil. Pathologie Biologie (Paris). 2009; 57: 470-476.
19. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N and Robert J. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. Journal of Clinical Oncology 1999; 17: 1105.
20. Garg MB, Sevester JC, Sakoff JA and Ackland SP. Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2002; 774: 223-230.
21. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R and Lacarelle B. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Therapeutic Drug Monitoring 2006; 28: 678-685.
22. Jiang H, Jiang J, Hu P and Hu Y. Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2002; 769: 169-176.
23. Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B and Mercier C. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemotherapy and Pharmacology 2011; 67: 49-56.
24. Schmiedt CW, Saba CF, Freeman KG and Edwards GL. Survey of dihydropyrimidine dehydrogenase activity based on uracil:dihydrouracil ratios in normal, tumor-bearing, and renal insufficient dogs. American Journal of Veterinary Research 2012; 73: 119-124.
25. Deporte R, Amiand M, Moreau A, Charbonnel C and Campion L. High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2006; 834(1-2): 170-177.
26. Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A and Lacarelle B. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. Journal of Clinical Pharmacy and Therapeutics 2004; 29: 307-315.
27. Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R and Tajima T. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathologica 1990; 81: 66-73.
28. Davis LE, Lenkinski RE, Shinkwin MA, Kressel HY and Daly JM. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism. Cancer 1993; 72: 3715-3722.
29. Zaharevitz DW, Grubb MF, Hyman R, Chisena C and Cysyk RL. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues. Journal of the National Cancer Institute 1993; 85: 662-666.
30. Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Renée N, Schneider M and Demard F. Dihydropyrimidine dehydrogenase activity in cancer patients. European Journal of Cancer 1993; 29A: 740-744.
31. Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renée N, Schneider M and Demard F. Influence of sex and age on fluorouracil clearance. Journal of Clinical Oncology 1992; 10: 1171-1175.
32. Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P and Milano G. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. European Journal of Cancer 1998; 34: 92-97.